Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.94 |
| ▸ | MLNR | O43193 | 1/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.94 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.94 |
| ▸ | CCKAR | P32238 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | GHSR | Q92847 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.94 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | CTSD | P07339 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | PGC | P20142 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL27785902 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL341700 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL291519 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL28121836 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL7993264 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459989-B2 | Antibody therapies for human immunodeficiency virus (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | JERICHO SCIENCES LLC (US) | 2025-05-29 | — | — | US | claimed |
| EP-4394098-A1 | PREPARATION METHOD FOR COLLAGEN FIBER, COLLAGEN FIBER, AND USE | Zhejiang Heuristic New Material Technology Limited Liability Company (CN) | 2024-07-03 | — | — | EP | claimed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2023164293-A1 | METHODS FOR VIRAL INFECTIONS | JERICHO SCIENCES, LLC (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230000884-A1 | COMBINATION THERAPY FOR TREATING COVID-19 | Luckwel Pharmaceuticals Inc. | 2023-01-05 | — | — | US | claimed |
| EP-3656384-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | claimed |
| US-20220025021-A1 | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-01-27 | — | — | US | claimed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12617843-B2 | Human broadly neutralizing antibodies against the membrane-proximal external region of HIV Env for vaccine design and intervention | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731212-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | Sagimet Biosciences Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4730340-A1 | METHOD FOR DETERMINING THE PRESENCE OF A PROBE SEQUENCE IN A TARGET NUCLEOTIDE SEQUENCE | Institut Pasteur de Dakar (SN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102464-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | SHANGHAI PUYOU BIOMEDICAL CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| EP-3974831-A1 | METHODS FOR DETECTING THE PRESENCE OF A BACTERIUM IN A WHOLE BLOOD SAMPLE | T2 Biosystems, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| CN-114081867-A | Method for improving drug loading capacity of microspheres | 中国药科大学 | 2022-02-25 | — | — | CN | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3955921-A1 | 2-IMINO-5-OXO-IMIDAZOLIDINE INHIBITORS OF HIV PROTEASE | GILEAD SCIENCES, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220025021-A1 | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | ZC3HAV1, ZC3HAV1L, ZFR | UGT1A1 3785/4885MLNR 4368/4885NR1I2 3306/4885 |
| US-12617843-B2 | Human broadly neutralizing antibodies against the membrane-proximal external region of HIV Env for vaccine design and intervention | CD4, VSIG8, IGLV6-57 | UGT1A1 4033/4885MLNR 4497/4885NR1I2 3805/4885 |
| US-20260102464-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | APOL1, APOB, LDLR | UGT1A1 4523/4885MLNR 4808/4885NR1I2 1886/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | UGT1A1 1885/4885MLNR 3606/4885NR1I2 2239/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | UGT1A1 923/4885MLNR 181/4885NR1I2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.